Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs GeneDx Holdings Corp — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $27.43, while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| RDTE | WGS | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $34.10 | $167.51 |
52-Week Low | $26.40 | $34.51 |
Market Cap | — | $2.58B |
Enterprise Value | — | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE trades at $27.84, down 0.32% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF maintains an aggressive dividend distribution strategy with multiple payments in 2026, though key valuation metrics remain unavailable for analysis. Technical indicators show oversold conditions with RSI at 27.52 but strong bearish momentum from moving averages.
The outlook remains cautious due to structural capital erosion risks identified by analysts. While the high dividend yield near 39% attracts income investors, the covered call strategy caps upside potential and exposes investors to full downside risk. Recent analyst reports highlight concerns about NAV deterioration and failure to capture index rallies.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
